GLP-1 weight-loss questions, answered briefly

Four are licensed and sold by regulated UK online providers: Mounjaro (tirzepatide, weekly injection), Wegovy (semaglutide, weekly injection), the Wegovy pill (oral semaglutide, daily) and Foundayo (orforglipron, daily tablet, licensed August 2026). Start with the what-is guides: Mounjaro, Wegovy, Wegovy pill, Foundayo.

Today's lowest first-month prices at starting doses: Mounjaro from £94, Wegovy injection from £53, Wegovy pill from £49, Foundayo from £49 (checked 27 Aug 2026, re-checked every 12 hours). The ongoing price matters more than the first month: understanding true cost and the UK price index.

There is no universal best: trial averages differ, but tolerability, routine, health history and budget decide what works for an individual, which is why these are prescription-only. The evidence is set out in Mounjaro vs Wegovy, Foundayo vs Mounjaro, Foundayo vs Wegovy pill and pill vs injection.

The licences cover adults with BMI 30+, or 27+ with a weight-related condition, assessed and verified by a prescriber. Full picture, including how online providers verify: GLP-1 eligibility in the UK.

Partially and unevenly: tirzepatide is rolling out in phases under NICE guidance, semaglutide is available via some specialist services, and Foundayo is private-only at launch. Most people currently access them privately; check the NHS website or your GP for your area.

Neither is universally better. Injections currently hold the higher trial averages; tablets win on routine, and the two tablets differ sharply from each other on food rules. See pill vs injection and Foundayo vs Wegovy pill.

Predominantly gastrointestinal for all four: nausea, constipation, diarrhoea and vomiting, most common around dose increases, with rarer serious risks listed in each patient information leaflet. Each what-is guide summarises its medicine's profile with sources, and suspected side effects should be reported via the MHRA Yellow Card scheme.

Trials measure averages over 64-72 weeks and individual variation is wide. The headline figures with their trials and caveats are in each what-is guide; be sceptical of any provider promising a schedule.

Two reasons: first-order discounts for new customers, and dose ladders where higher doses cost more. Both are visible in our tables, which separate first-month and ongoing prices per dose: true cost guide.

The ones we list are read from providers' own pages by our automatic checker, with first-seen and last-verified dates: Mounjaro, Wegovy, Wegovy pill, Foundayo codes. Anything from an unverifiable coupon site deserves suspicion.

Yes, prescriber-led, and the details matter: there is no universal dose-conversion chart, and switching provider usually forfeits new-customer pricing. Switching GLP-1 medicines covers both.

Trials that withdrew treatment (for example SURMOUNT-4 for tirzepatide) recorded average weight regain over the following year, which is why stopping and restarting is a prescriber conversation rather than a light switch. A dedicated guide is planned; until then the trial sources are linked from each what-is page.

Check the GPhC register for the pharmacy and the CQC for the prescribing service, both free and linked with exact register numbers on every provider we list: the five checks.

Every price is read from the provider's own public pages, dated, and re-checked every 12 hours; every clinical fact carries a primary source. The rules we hold ourselves to are published in the editorial policy and methodology, and the dataset is free at the data feed.